News

Graviton Bioscience has launched a Phase 2 clinical trial to test its experimental therapy GV101 in people with Friedreich’s ataxia (FA). The trial (NCT07870590) is planned to enroll 48 people with FA, ages 16 to 40, who are able to walk (with or without assistance) and who…

A first-in-human trial testing Adjuvia Therapeutics‘ ATI-105 for Friedreich’s ataxia (FA) — an oral therapy derived from bacteria and engineered to cross a barrier protecting the brain — is now underway, having dosed its first participant. The Phase 1 study (NCT07869654), sponsored by the California-based biotech, is…

Solid Biosciences‘ experimental gene therapy for Friedreich’s ataxia (FA), called SGT-212, has been granted orphan drug status in the European Union. This designation aims to offer additional incentives to companies investing in treatments for rare diseases, where the small number of patients can make it hard for drug…

Using an experimental gene-editing approach, a team of U.S. scientists was able to successfully and precisely remove the genetic defect underlying most cases of Friedreich’s ataxia (FA) in several laboratory cell models. According to the researchers, the strategy achieved “precise editing” — as high as 98.2% — among connective…

People with Friedreich’s ataxia (FA) develop thickening of the heart muscle wall early on, followed by a gradual decline in pumping function that can take up to three decades to appear, according to a study that examined more than 25 years of echocardiogram records from nearly 600 FA patients.

A new documentary chronicling the story of two men with Friedreich’s ataxia (FA) as they undertake a seemingly impossible athletic endeavor — cycling across mountains, with a rare muscle disease — will premiere at a film festival in California later this month. The movie, “The Highest Road,” is…

Lexeo Therapeutics has acquired the private, clinical-stage company Mantle Therapeutics, gaining the rights to several experimental therapies Mantle had been developing for Friedreich’s ataxia (FA) — including one already in early clinical testing. In announcing the deal, which could be worth more than $21 million, Lexeo also heralded…

International Ataxia Awareness Day on Sept. 25 aims to bring people together worldwide to raise awareness of ataxia — a group of diseases that includes Friedreich’s ataxia (FA) — and the National Ataxia Foundation (NAF) is urging everyone to take part through advocacy, social media, virtual and in-person…

Replacing myeloid cells — a group of immune cells that includes microglia in the brain and spinal cord and macrophages in other tissues — with healthy, donor-derived cells improved neurological and heart abnormalities in a mouse model of Friedreich’s ataxia (FA), a U.S. study found. Microglia and macrophages can become…

Failure in a protein modification process needed to maintain the function of a brain receptor is a key early mechanism leading to Friedreich’s ataxia, a mouse study showed. The process, known as palmitoylation, links the loss of frataxin, the protein missing in people with FA, to nerve cell vulnerability…